Page results
-
Having proton beam therapy: information for children aged 9-12 patient information
-
Our neonatal service is a recognised centre of excellence caring for acutely ill and preterm babies from our local area and beyond.
-
Arif Ahmed is an entrepreneur and private equity investor in healthcare, technology, e-commerce and B2B services companies. He has a proven track record of scaling innovation in complex regulatory environments.
-
Having proton beam therapy: information for teenagers aged 13-17 patient information
-
This page has been written for patients who are having radioactive iodine (131I) ablation and/or radioiodine treatment for thyroid cancer.
-
At University College London Hospitals NHS Foundation Trust (UCLH) we value our reputation for top quality care and financial probity and conduct our business in an ethical manner.
-
This page is for parents and carers whose child is having radiotherapy treatment to the pelvis.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the spine (backbone).
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
This information is for patients receiving steroids for immunotherapy toxicity.
File results
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0357 - Multiple myeloma treatments